https://scholars.lib.ntu.edu.tw/handle/123456789/458568
標題: | Risk factors of hypersensitivity to carboplatin in patients with gynecologic malignancies | 作者: | Tai Y.-H. YI-JOU TAI HENG-CHENG HSU Lee S.-P. Chen Y.-Y. YING-CHENG CHIANG YU-LI CHEN CHI-AN CHEN WEN-FANG CHENG |
公開日期: | 2017 | 卷: | 8 | 期: | 11 | 來源出版物: | Frontiers in Pharmacology | 摘要: | We evaluated the prevalence of and risk factors for hypersensitivity reactions related to carboplatin, which is commonly used to treat gynecological malignancies. All women with pathologically documented ovarian, fallopian tube, or primary peritoneal cancer treated with carboplatin alone or a carboplatin-based combination chemotherapy regimen at a single hospital between January 2006 and December 2013 were retrospectively recruited. We analyzed the incidence, characteristics, risk factors, management, and outcomes of carboplatin-related hypersensitivity reactions among these patients. Among 735 eligible women, 75 (10.2%) experienced a total of 215 carboplatin-related hypersensitivity reaction events. The annual incidence of carboplatin-related hypersensitivity reactions gradually increased from 0.88% in 2006 to 5.42% in 2013. The incidence of carboplatin-related hypersensitivity was higher in patients with advanced stage disease (P < 0.001, Kruskal-Wallis test), serous and mixed histological types (P = 0.003, Kruskal-Wallis test), malignant ascites (P = 0.009, chi-square test), and history of other drug allergy (P < 0.001, chi-square test). Compared to women without hypersensitivity reactions, women who experienced hypersensitivity reactions had a significantly greater median cycle number (12 vs. 6, P < 0.001, independent sample t-test) and dose (6,816 vs. 3,844 mg, P < 0.001, independent sample t-test). The cumulative incidence of carboplatin-related hypersensitivity reactions dramatically increased with > 8 cycles or dose > 3,500 mg. Therefore, disease severity, histological type, malignant ascites, past drug allergies, and cumulative carboplatin dose are risk factors for carboplatin-related hypersensitivity reactions. Such reactions could potentially be reduced or prevented by slowing the infusion rate and using a desensitization protocol involving anti-allergy medications. ? 2017 Tai, Tai, Hsu, Lee, Chen, Chiang, Chen, Chen and Cheng. |
URI: | 2-s2.0-85033571298 https://scholars.lib.ntu.edu.tw/handle/123456789/458568 |
ISSN: | 1663-9812 | DOI: | 10.3389/fphar.2017.00800 | SDG/關鍵字: | carboplatin; adolescent; adult; aged; Article; cancer staging; controlled study; disease severity; drug hypersensitivity; female; female genital tract cancer; histology; human; incidence; major clinical study; malignant ascites; middle aged; ovary cancer; peritoneum cancer; retrospective study; Taiwan; uterine tube tumor |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。